Atlas Trials

Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax

Clinical trial NCT06090786 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06090786
Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Status
NOT_YET_RECRUITING
Phase
Not Applicable
Study type
INTERVENTIONAL
AML, AdultMinimal Residual Disease
Start date
2024-07-01
Primary completion
2027-07-01
Enrollment
225

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.